ClinicalTrials.gg
CompletedNCT02905266Updated Dec 17, 2020Results posted

A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma

A Phase 3 interventional study of Nivolumab and Ipilimumab in Melanoma, sponsored by Bristol-Myers Squibb. Completed at 16 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-17.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 62 under way, 9 of them phase 3. Nivolumab · Melanoma.

Enrollment
40th of 142
106 · median 50
Started
2016
with 15 others
Phase 3
19 of 142
2 open now
Registered
38th of 142
by date
Lead sponsor
23 of 142
Bristol-Myers Squibb

Among the 142 studies testing nivolumab in Melanoma, this one is the 40th largest by enrollment, is one of 16 that started in 2016, is one of 19 in phase 3, and was the 38th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies testing nivolumab in Melanoma, or all of them as a file.
02

Study summary

This is a safety and efficacy study of different administration regimens of nivolumab plus Ipilimumab in subjects with previously untreated, unresectable or metastatic melanoma.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Males and Females, ages 15 years ≥ of age (Except where local regulations and/or institutional policies do not allow for subjects \< 18 years of age to participate)
  • Subjects must have been diagnosed with stage III or/and stage IV confirmed melanoma that is unresectable or
  • (ECOG) performance status of 0-1
  • Subjects have not been treated by systemic anticancer therapy for unresectable or metastatic melanoma

Exclusion criteria

Exclusion Criteria:

  • Subjects with active or
  • Subjects with ocular melanoma
  • Subjects with active, known or suspected disease

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Nivolumab and Ipilimumab Concomitant Administration

    Followed by Nivolumab monotherapy

    Biological: Nivolumab · Biological: Ipilimumab

  • Experimental
    Nivolumab and Ipilimumab Sequential Administration

    Followed by Nivolumab monotherapy

    Biological: Nivolumab · Biological: Ipilimumab

Interventions

  • BiologicalNivolumab

    -Specified dose on specified days

  • BiologicalIpilimumab

    -Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Affected by Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ)

    This outcome describes the percentage of participants experiencing at least 1 AE in the MedDRA Anaphylactic Reaction broad scope SMQ. Such AEs include any acute systemic reaction characterized by a large list of terms, including (but not limited to) pruritus, urticaria, flushing, hypotension, respiratory distress, and vascular insufficiency. It also includes other signs and symptoms such as asthma, choking sensation, coughing, sneezing, and difficulty breathing due to laryngeal spasm and/or bronchospasm. Less frequent clinical presentations are also captured and include hyperventilation, sensation of foreign body, and ocular edema.

    Time frame: Within 2 days from administration of any of the 4 doses in part 1 period (approximately 12 weeks)

Secondary outcomes

  1. Percentage of Participants Affected by AEs in the Narrow Scope MedDRA Anaphylactic Reaction SMQ

    This outcome describes the percentage of participants experiencing at least 1 AE in the MedDRA Anaphylactic Reaction narrow scope SMQ. The narrow scope SMQ is composed of a large list of terms, including (but not limited to) anaphylactic shock and reaction, shock and shock symptoms, and circulatory collapse, among the others.

    Time frame: Within 2 days from administration of any of the 4 doses in part 1 period (approximately 12 weeks)

  2. Percentage of Participants Affected by Hypersensitivity/Infusion Reaction Select AEs

    This outcome describes the percentage of participants experiencing at least 1 AE in the Hypersensitivity/Infusion select AEs category. The select AEs consist of a list of preferred terms defined by the Sponsor and represent AEs with a potential immune-mediated etiology. The following 5 MedDRA preferred terms are included in the hypersensitivity/infusion reaction select AE category: Anaphylactic Reaction, Anaphylactic Shock, Bronchospasm, Hypersensitivity, and Infusion Related Reaction

    Time frame: Within 2 days from administration of any of the 4 doses in part 1 period (approximately 12 weeks)

  3. Percentage of Participants Affected by All Causality Grade 3 - 5 AEs

    This outcome describes the percentage of participants who experienced at least 1 AE of Grade 3 or higher defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria

    Time frame: From initial dose of study treatment and within 30 days of the last dose of study treatment (approximately 25 months)

  4. Percentage of Participants Affected by Drug-related Grade 3 - 5 AEs

    This outcome describes the percentage of participants who experienced at least 1 Drug-related AE of Grade 3 or higher defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria

    Time frame: From initial dose of study treatment and within 30 days of the last dose of study treatment (approximately 25 months)

  5. Geometric Mean Concentration of Ipilimumab at End of Infusion (EOI)

    Time frame: From Cycle 1, Day 1 to Cycle 4, Day 1 (approximately 9 weeks). Each cycle lasts 3 weeks. Cycle 1 day 1, Cycle 2 day 1 and Cycle 4 day 1 values reported.

  6. Geometric Mean Concentration of Nivolumab at End of Infusion (EOI)

    Time frame: From Cycle 1, Day 1 to Cycle 4, Day 1 (approximately 9 weeks). Each cycle lasts 3 weeks. Cycle 1 day 1, Cycle 2 day 1 and Cycle 4 day 1 values reported

  7. Geometric Mean Trough Concentration of Ipilimumab

    Time frame: From Cycle 2, Day 1 to Cycle 4, Day 1 (approximately 6 weeks). Each cycle lasts 3 weeks.

  8. Geometric Mean Trough Concentration of Nivolumab

    Time frame: From Cycle 2, Day 1 to Cycle 4, Day 1 (approximately 6 weeks). Each cycle lasts 3 weeks.

  9. Objective Response Rate (ORR)

    The ORR is defined as the proportion of participants with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR). The BOR is defined as the best response designation, as determined by the investigator, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of subsequent anti-cancer therapy, whichever occurs first.

    Time frame: Week 12 following randomization, every 8 weeks for the first 12 months and then every 12 weeks until disease progression (approximately 20 months)

  10. Progression Free Survival (PFS)

    PFS is defined as the time between the date of randomization and the first date of documented progression, as determined by the investigator, or death due to any cause, whichever occurs first.

    Time frame: From the date of randomization to the first date of documented progression (approximately 26 months)

07

Results

Posted Jan 8, 2019

Participant flow

Treatment Phase Part 1
Participant flow — Treatment Phase Part 1
MilestoneFixed Ratio CombinationSequential Combination
Started5353
Completed2430
Not completed2923
Withdrew: Participant withdrew consent10
Withdrew: Disease progression67
Withdrew: Study drug toxicity2216
Transition From Part 1 to Part 2
Participant flow — Transition From Part 1 to Part 2
MilestoneFixed Ratio CombinationSequential Combination
Started2430
Completed2022
Not completed48
Withdrew: Adverse event unrelated to study drug10
Withdrew: Disease progression21
Withdrew: Study drug toxicity04
Withdrew: Death01
Withdrew: Participant withdrew consent01
Withdrew: Adverse event11
Maintenance Phase Part 2
Participant flow — Maintenance Phase Part 2
MilestoneFixed Ratio CombinationSequential Combination
Started2022
Completed814
Not completed128
Withdrew: Disease progression92
Withdrew: Study drug toxicity34
Withdrew: Maximum clinical benefit02

Outcome measures

SecondaryPercentage of Participants Affected by AEs in the Narrow Scope MedDRA Anaphylactic Reaction SMQ

This outcome describes the percentage of participants experiencing at least 1 AE in the MedDRA Anaphylactic Reaction narrow scope SMQ. The narrow scope SMQ is composed of a large list of terms, including (but not limited to) anaphylactic shock and reaction, shock and shock symptoms, and circulatory collapse, among the others.

Time frame:
Within 2 days from administration of any of the 4 doses in part 1 period (approximately 12 weeks)
Reported as:
Number · Percent of Participants
Percentage of Participants Affected by AEs in the Narrow Scope MedDRA Anaphylactic Reaction SMQ
Percent of ParticipantsFixed Ratio CombinationSequential Combination
Percentage of Participants Affected by AEs in the Narrow Scope MedDRA Anaphylactic Reaction SMQ0.0 (0.0 to 6.7)0.0 (0.0 to 6.7)
Statistical analysis
  • Fixed Ratio Combination vs Sequential Combination · Percent difference in incidence rates: 0.0 · 95% CI 0.0 to 0.0Fixed Ratio Combination over Sequential Combination
SecondaryPercentage of Participants Affected by Hypersensitivity/Infusion Reaction Select AEs

This outcome describes the percentage of participants experiencing at least 1 AE in the Hypersensitivity/Infusion select AEs category. The select AEs consist of a list of preferred terms defined by the Sponsor and represent AEs with a potential immune-mediated etiology. The following 5 MedDRA preferred terms are included in the hypersensitivity/infusion reaction select AE category: Anaphylactic Reaction, Anaphylactic Shock, Bronchospasm, Hypersensitivity, and Infusion Related Reaction

Time frame:
Within 2 days from administration of any of the 4 doses in part 1 period (approximately 12 weeks)
Reported as:
Number · Percent of Participants
Percentage of Participants Affected by Hypersensitivity/Infusion Reaction Select AEs
Percent of ParticipantsFixed Ratio CombinationSequential Combination
Percentage of Participants Affected by Hypersensitivity/Infusion Reaction Select AEs7.59.4
SecondaryPercentage of Participants Affected by All Causality Grade 3 - 5 AEs

This outcome describes the percentage of participants who experienced at least 1 AE of Grade 3 or higher defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria

Time frame:
From initial dose of study treatment and within 30 days of the last dose of study treatment (approximately 25 months)
Reported as:
Number · Percent of participants
Percentage of Participants Affected by All Causality Grade 3 - 5 AEs
Percent of participantsFixed Ratio CombinationSequential Combination
Percentage of Participants Affected by All Causality Grade 3 - 5 AEs69.856.6
SecondaryPercentage of Participants Affected by Drug-related Grade 3 - 5 AEs

This outcome describes the percentage of participants who experienced at least 1 Drug-related AE of Grade 3 or higher defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria

Time frame:
From initial dose of study treatment and within 30 days of the last dose of study treatment (approximately 25 months)
Reported as:
Number · Percent of participants
Percentage of Participants Affected by Drug-related Grade 3 - 5 AEs
Percent of participantsFixed Ratio CombinationSequential Combination
Percentage of Participants Affected by Drug-related Grade 3 - 5 AEs58.547.2
SecondaryGeometric Mean Concentration of Ipilimumab at End of Infusion (EOI)
Time frame:
From Cycle 1, Day 1 to Cycle 4, Day 1 (approximately 9 weeks). Each cycle lasts 3 weeks. Cycle 1 day 1, Cycle 2 day 1 and Cycle 4 day 1 values reported.
Reported as:
Geometric mean · micrograms per milliliter (ug/mL)
Geometric Mean Concentration of Ipilimumab at End of Infusion (EOI)
micrograms per milliliter (ug/mL)Fixed Ratio CombinationSequential Combination
Cycle 1 Day 160.4 ± 93.061.5 ± 72.3
Cycle 2 Day 166.8 ± 13472.1 ± 71.8
Cycle 4 Day 177.9 ± 94.284.6 ± 104
SecondaryGeometric Mean Concentration of Nivolumab at End of Infusion (EOI)
Time frame:
From Cycle 1, Day 1 to Cycle 4, Day 1 (approximately 9 weeks). Each cycle lasts 3 weeks. Cycle 1 day 1, Cycle 2 day 1 and Cycle 4 day 1 values reported
Reported as:
Geometric mean · micrograms per milliliter (ug/mL)
Geometric Mean Concentration of Nivolumab at End of Infusion (EOI)
micrograms per milliliter (ug/mL)Fixed Ratio CombinationSequential Combination
Cycle 1 Day 120.9 ± 77.321.8 ± 117
Cycle 2 Day 124.2 ± 12222.4 ± 101
Cycle 4 Day 127.9 ± 79.827.4 ± 79.9
SecondaryGeometric Mean Trough Concentration of Ipilimumab
Time frame:
From Cycle 2, Day 1 to Cycle 4, Day 1 (approximately 6 weeks). Each cycle lasts 3 weeks.
Reported as:
Geometric mean · micrograms per milliliter (ug/mL)
Geometric Mean Trough Concentration of Ipilimumab
micrograms per milliliter (ug/mL)Fixed Ratio CombinationSequential Combination
Cycle 2 Day 110.8 ± 30.29.94 ± 38.9
Cycle 4 Day 116.5 ± 36.913.7 ± 46.0
SecondaryGeometric Mean Trough Concentration of Nivolumab
Time frame:
From Cycle 2, Day 1 to Cycle 4, Day 1 (approximately 6 weeks). Each cycle lasts 3 weeks.
Reported as:
Geometric mean · micrograms per milliliter (ug/mL)
Geometric Mean Trough Concentration of Nivolumab
micrograms per milliliter (ug/mL)Fixed Ratio CombinationSequential Combination
Cycle 2 Day 13.94 ± 56.62.75 ± 65.9
Cycle 4 Day 16.50 ± 44.64.05 ± 75.3
SecondaryObjective Response Rate (ORR)

The ORR is defined as the proportion of participants with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR). The BOR is defined as the best response designation, as determined by the investigator, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of subsequent anti-cancer therapy, whichever occurs first.

Time frame:
Week 12 following randomization, every 8 weeks for the first 12 months and then every 12 weeks until disease progression (approximately 20 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsFixed Ratio CombinationSequential Combination
Objective Response Rate (ORR)52.8 (38.6 to 66.7)60.4 (46.0 to 73.5)
Statistical analysis
  • Fixed Ratio Combination vs Sequential Combination · Percent difference of orrs: -7.5 · 95% CI -26.1 to 11.0Cochran-Mantel-Haenszel (CMH) method of weighting
  • Fixed Ratio Combination vs Sequential Combination · Odds ratio (or): 0.75 · 95% CI 0.35 to 1.58
SecondaryProgression Free Survival (PFS)

PFS is defined as the time between the date of randomization and the first date of documented progression, as determined by the investigator, or death due to any cause, whichever occurs first.

Time frame:
From the date of randomization to the first date of documented progression (approximately 26 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsFixed Ratio CombinationSequential Combination
Progression Free Survival (PFS)10.25 (2.96 to NA)NA (4.96 to NA)
Statistical analysis
  • Fixed Ratio Combination vs Sequential Combination · Hazard ratio (hr): 1.36 · 95% CI 0.78 to 2.37Stratified Cox proportional hazard model
PrimaryPercentage of Participants Affected by Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ)

This outcome describes the percentage of participants experiencing at least 1 AE in the MedDRA Anaphylactic Reaction broad scope SMQ. Such AEs include any acute systemic reaction characterized by a large list of terms, including (but not limited to) pruritus, urticaria, flushing, hypotension, respiratory distress, and vascular insufficiency. It also includes other signs and symptoms such as asthma, choking sensation, coughing, sneezing, and difficulty breathing due to laryngeal spasm and/or bronchospasm. Less frequent clinical presentations are also captured and include hyperventilation, sensation of foreign body, and ocular edema.

Time frame:
Within 2 days from administration of any of the 4 doses in part 1 period (approximately 12 weeks)
Reported as:
Number · Percent of Participants
Percentage of Participants Affected by Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ)
Percent of ParticipantsFixed Ratio CombinationSequential Combination
Percentage of Participants Affected by Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ)15.1 (6.7 to 27.6)17.0 (8.1 to 29.8)
Statistical analysis
  • Fixed Ratio Combination vs Sequential Combination · Cochran-mantel-haenszel odds ratio: 0.87 · 95% CI 0.30 to 2.49Fixed Ratio Combination over Sequential Combination
  • Fixed Ratio Combination vs Sequential Combination · Percent difference in incidence rates: -1.9 · 95% CI -16.0 to 12.2Fixed Ratio Combination over Sequential Combination

Adverse events

Collected over From first dose to 100 days following administration of the last dose (approximately 27 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fixed Ratio Combination14/53 (26.4%)35/53 (66%)51/53 (96.2%)
Sequential Combination14/53 (26.4%)35/53 (66%)51/53 (96.2%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventFixed Ratio CombinationSequential Combination
PyrexiaGeneral disorders8/530/53
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/537/53
Hepatocellular injuryHepatobiliary disorders6/533/53
ColitisGastrointestinal disorders4/534/53
Immune-mediated enterocolitisGastrointestinal disorders3/531/53
VomitingGastrointestinal disorders3/531/53
ArthralgiaMusculoskeletal and connective tissue disorders3/531/53
DyspnoeaRespiratory, thoracic and mediastinal disorders0/533/53
PneumonitisRespiratory, thoracic and mediastinal disorders3/531/53
ThyroiditisEndocrine disorders2/531/53
Most frequent other events
Showing 10 of 60
Most frequent other events
EventFixed Ratio CombinationSequential Combination
DiarrhoeaGastrointestinal disorders16/5325/53
AstheniaGeneral disorders17/5320/53
PyrexiaGeneral disorders14/5318/53
PruritusSkin and subcutaneous tissue disorders9/5317/53
HeadacheNervous system disorders8/5315/53
RashSkin and subcutaneous tissue disorders15/5312/53
CoughRespiratory, thoracic and mediastinal disorders13/537/53
NauseaGastrointestinal disorders9/5312/53
VomitingGastrointestinal disorders9/5312/53
HypothyroidismEndocrine disorders11/538/53

Baseline characteristics

All treated participants

Age, Continuous
Age, Continuous(years)Fixed Ratio CombinationSequential CombinationTotal
Mean58.1 ± 14.556.3 ± 14.657.2 ± 14.5
Sex: Female, Male
Sex: Female, Male(Participants)Fixed Ratio CombinationSequential CombinationTotal
Female182644
Male352762
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Fixed Ratio CombinationSequential CombinationTotal
Hispanic or Latino112
Not Hispanic or Latino262854
Unknown or Not Reported262450
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Fixed Ratio CombinationSequential CombinationTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White485098
More than one race000
Unknown or Not Reported437
08

Study locations

16 sites
  • Melanoma Institute Australia
    North Sydney, New South Wales, Australia
  • Greenslopes Private Hospital
    Greenslopes, Queensland, Australia
  • Cabrini Hospital
    Malvern, Victoria, Australia
  • Local Institution
    Lyon Cedex 08, 69373, France
  • Hopital De La Timone
    Marseille Cedex 5, 13385, France
  • Local Institution
    Nantes Cedex 1, 44093, France
  • Local Institution
    Paris Cedex 14, 75679, France
  • Hopital Saint Louis
    Paris, 75475, France
  • Hopital Trousseau - Chru Tours
    Tours, 37044, France
  • Istituto Nazionale Per La Ricerca Sul Cancro - Oncologia Med
    Genova, 16128, Italy
  • Istituto Scientifico Romagnolo Per Lo Studio E Cura Tumori
    Meldola (FC), 47014, Italy
  • Istituto Europeo Di Oncologia
    Milan, 20141, Italy
  • Azienda Ospedaliera Citta della Salute e della Scienza
    Torino, 10137, Italy
  • Local Institution
    Barcelona, 08036, Spain
  • Local Institution
    Madrid, 28007, Spain
  • Local Institution
    Sevilla, 41071, Spain
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Oct 2017, 11 months.

Results were first posted in Jan 2019, 1 year 2 months after primary completion.

Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 11 months is below that.

Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2016
First posted
Sep 19, 2016
StartActual
Oct 27, 2016
Primary completionActual
Oct 23, 2017
CompletionActual
Oct 25, 2019
Results first posted
Jan 8, 2019
Last update
Dec 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02905266
Responsible party
Sponsor
First posted
Sep 19, 2016
Start date
Oct 27, 2016
Primary completion
Oct 23, 2017
Completion
Oct 25, 2019
Results posted
Jan 8, 2019
Last update
Dec 17, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion